Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
- Primary intelligence (targeted KOL and stakeholder interviews to resolve the specific uncertainties in your thesis)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming (via LucidWargames) to stress-test theses and quantify scenario risk
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
November 20, 2025
Cardiovascular Today—November 20, 2025
November 20, 2025
Rare Disease Video Recap—November 20, 2025
November 20, 2025
Rare Disease Today—November 20, 2025
November 20, 2025
Cell and Gene Therapy Today—November 20, 2025
November 19, 2025
Neuroscience Today — November 19, 2025
November 19, 2025
Immunology Video Recap—November 19, 2025
November 19, 2025
Immunology Today—November 19, 2025
November 19, 2025
Lucid Diligence Brief: Avanzanite Bioscience €32m Series A
November 18, 2025
AI in Healthcare and Digital Health Video Recap—November 18, 2025
November 18, 2025
Obesity Today—November 18, 2025
November 18, 2025